title: Chemotherapy with carboplatin and paclitaxel after failure of primary chemotherapy for advanced thymic carcinoma. A report of three cases and review of the literature.
abstract: For patients with inoperable thymic carcinoma, multidrug chemotherapy containing cisplatin and an anthracycline is often used as first-line chemotherapy. A commonly applied regimen is cisplatin + doxorubicin + vincristine + cyclophosphamide (ADOC). There are relatively few reports on the use of carboplatin and paclitaxel as first-line chemotherapy for thymic carcinoma. In addition, little is known about its efficacy as second-line chemotherapy in patients with advanced thymic carcinoma. We here report on three patients with thymic carcinoma who were treated with carboplatin and paclitaxel as second-line chemotherapy after failure of ADOC. According to the Response Evaluation Criteria in Solid Tumors version 1.1, one patient achieved a partial response and two patients achieved stable disease. The median progression-free survival was 6.7 months and the median overall survival exceeded 3 years. Toxicities were well tolerated. Chemotherapy with carboplatin and paclitaxel appears to be effective as second-line chemotherapy for some persons with thymic carcinoma who fail ADOC.
authors: Keisuke
authors: K
authors: Watanabe
authors: Masaharu
authors: M
authors: Shinkai
authors: Hideto
authors: H
authors: Goto
authors: Sumiko
authors: S
authors: Yoshikawa
authors: Nobuhiro
authors: N
authors: Yamaguchi
authors: Yuu
authors: Y
authors: Hara
authors: Masahiro
authors: M
authors: Shinoda
authors: Yusuke
authors: Y
authors: Moriyama
authors: Bruce K
authors: BK
authors: Rubin
authors: Yoshiaki
authors: Y
authors: Ishigatsubo
authors: Takeshi
authors: T
authors: Kaneko
mesh_terms: D000368:Aged; D018943:Anthracyclines / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D016190:Carboplatin / Q000008:administration & dosage; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology; D000077143:Docetaxel; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D000077146:Irinotecan; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D017239:Paclitaxel / Q000008:administration & dosage; D012189:Retrospective Studies; D043823:Taxoids / Q000008:administration & dosage; D013945:Thymoma / Q000188:drug therapy / Q000473:pathology; D013953:Thymus Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D018943:Anthracyclines; D043823:Taxoids; D000077143:Docetaxel; D000077146:Irinotecan; C055866:amrubicin; D016190:Carboplatin; D017239:Paclitaxel; D002166:Camptothecin